R-2-hydroxyglutarate as the key effector of IDH mutations promoting oncogenesis.
Cancer Cell
; 23(3): 274-6, 2013 Mar 18.
Article
em En
| MEDLINE
| ID: mdl-23518346
ABSTRACT
The tumor-associated isocitrate dehydrogenase (IDH) mutants are unique in that they have lost their normal catalytic activity and gained a novel function to produce R-2-hydroxyglutarate (R-2-HG). A recent study now shows that R-2-HG can reversibly promote leukemogenesis in vitro, suggesting a therapeutic potential of targeting mutant IDH1 and IDH2.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Idioma:
En
Ano de publicação:
2013
Tipo de documento:
Article